
XOMA (XOMA) Stock Forecast & Price Target
XOMA (XOMA) Analyst Ratings
Bulls say
XOMA Royalty Corp is projected to experience significant revenue growth, with a forecasted increase of over 20% annually through 2026, driven by commercial sales ramps and new product launches. The company's revenue rose dramatically from $4.8 million in 2023 to $28.5 million in 2024, thanks to enhanced income from purchased receivables and customer contracts. Looking forward, XOMA anticipates generating $49.0 million in revenue by 2026, along with a net income of $2.4 million, bolstered by the contributions of earlier-stage assets and possible milestone payments.
Bears say
XOMA Royalty Corp has experienced revenue and net earnings variability largely due to the unpredictable nature of the international biotechnology market and external economic factors, which could adversely affect the company's operations and demand for its services. The potential for failed clinical trials and challenges in securing adequate funding for drug development presents critical risks that may hinder the company’s growth prospects and stock performance. Additionally, the departure of key executives with extensive industry knowledge could create operational challenges and undermine investor confidence in XOMA's future potential.
This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.
XOMA (XOMA) Analyst Forecast & Price Prediction
Start investing in XOMA (XOMA)
Order type
Buy in
Order amount
Est. shares
0 shares